The Partnership : The Making of Goldman Sachs
The inside story of one of the world's most powerful financial Institutions Now with a new foreword and final chapter, The Partnership chronicles the most important periods in Goldman Sachs's history and the individuals who built one of the world's largest investment banks. Charles D. Ellis, who worked as a strategy consultant to Goldman Sachs for more than thirty years, reveals the secrets behind the firm's continued success through many life-threatening changes. Disgraced and nearly destroyed in 1929, Goldman Sachs limped along as a break-even operation through the Depression and WWII. But with only one special service and one improbable banker, it began the stage-by-stage rise that took the firm to global leadership, even in the face of the world-wide credit crisis.
- Paperback | 753 pages
- 138 x 212 x 42mm | 639.56g
- 29 Sep 2009
- Penguin Books
- London, England, United Kingdom
- Updated, Revised
" Rich with insider lore as well as the closed-door dramas of partnership clashes." -"The New York Times Book Review" "Exhaustively researched . . . paints a convincing picture of an institution that has got most of the important things right." -"The Economist"
About Charles D Ellis
Charles D. Ellis is a consultant to large institutional investors and government agencies. For thirty years he was managing partner of Greenwich Associates, an international business strategy consulting firm he founded that serves virtually all the leading financial service organizations around the world. Ellis earned his M.B.A. from Harvard University and his Ph.D. from New York University. He has taught investment management courses at Harvard and Yale and is the author of twelve books, mostly on investing, and has written nearly one hundred articles for business and professional magazines. Ellis has served on the boards of Harvard Business School and Phillips Exeter Academy. A past trustee of Yale University and Chair of its investment committee, he is trustee of Robert Wood Johnson Foundation, director of Vanguard, and chair of the Whitehead Institute of Biomedical Research and consults on investing with major institutions in Asia, Europe, and North America.